drugset / Trial / NCT00421044

A Study of Patupilone in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Function

NCT00421044

Phase 1 Completed 14 enrolled Novartis Pharmaceuticals
Non-randomizedParallel-groupOpen-labelTreatment

Summary

Patients who participated in the core EPO2121 study and did not clinically progress may participate in this extension protocol to further evaluate the safety, tolerability, and efficacy of patupilone.

Timeline

Start
2006-05
Primary completion
2008-02
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Patupilone Small molecule

Indications